Clinical relevance of botulinum toxin immunogenicity

BioDrugs

Volumn 26, Issue 2, 2012, Pages

  Benecke, Reiner ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Botulinum toxins

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; BOTULINUM TOXIN A ANTIBODY; BOTULINUM TOXIN B; COSMETIC; EXCIPIENT; NEUTRALIZING ANTIBODY; TOXIN ANTIBODY; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ANTIBODY PRODUCTION; BLEPHAROSPASM; CERVICAL DYSTONIA; DETRUSOR DYSSYNERGIA; DIAGNOSTIC ERROR; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; IMMUNOPRECIPITATION; MEDICATION ERROR; MOTOR DYSFUNCTION; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SPASTICITY;

ANIMALS; ANTIBODIES, NEUTRALIZING; BOTULINUM TOXINS, TYPE A; CLOSTRIDIUM BOTULINUM; HUMANS; MOVEMENT DISORDERS;

EID: 84857823034     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11599840-000000000-00000     Document Type: Review

References (72)

1. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 1980; 17: 21-5
2. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011; 18: 5-18
3. Novak I, Campbell L, Boyce M, et al. Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: International consensus statement. Eur J Neurol 2010; 17 Suppl. 2: 94-108
4. Simpson DM, Blitzer A, Brashear A, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1699-706
5. Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1691-8
6. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004; 19 Suppl. 8: S92-100
7. National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health. Myasthenia gravis fact sheet [online]. Available from URL: Http://www.ninds.nih.gov/disorders/myasthenia-gravis/detail-myas thenia-gravis.htm [Accessed 2011 Jan 26]
8. KrommingaA, SchellekensH. Antibodies against erythropoietin and other proteinbased therapeutics: An overview. Ann N Y Acad Sci 2005; 1050: 257-65
9. Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol 2002; 48: 26-9
10. Sharma SK, Fu FN, Singh BR. Molecular properties of a hemagglutinin purified from type A Clostridium botulinum. J Protein Chem 1999; 18: 29-38
11. Eisele KH, Fink K, Vey M, et al. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 2011; 57: 555-65
12. Lee J-C, Yokota K, Arimitsu H, et al. Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 2005; 151: 3739-47
13. Kukreja R, Chang T-W, Cai S, et al. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon 2009; 53: 616-24
14. Atassi MZ. On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxinhaemagglutinin. Microbiology 2006; 152: 1891-5
15. Frevert J. Content of botulinum neurotoxin in Botox-/Vistabel-, Dysport-/ Azzalure-, and Xeomin-/Bocouture-. Drugs R D 2010; 10: 67-73
16. Sun Y, Wang L, Singh BR. Botulinum neurotoxin type A complex proteins bind to neuronal as well as non-neuronal cells [poster]. 14th International Congress of Parkinson's Disease and Movement Disorders; 2010 Jun 13-17; Buenos Aires, Argentina
17. Atassi MZ. Basic immunological aspects of botulinum toxin therapy. Mov Disord 2004; 19 Suppl. 8: S68-84
18. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53: 1431-8
19. Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 2003; 250: 967-9
20. Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res 2006; 9: 145-8
21. Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/ NeuroBloc. Eur J Neurol 2006; 13 Suppl. 1: 11-5
22. Kamm C, Benecke R. Individualized management of cervical dystonia with different serotypes of botulinum toxin: Recent therapeutic advances and risk development of neutralizing antibodies. Eur Neurol J 2010; 2: 49-54
23. Borodic G, Johnson E, Goodnough M, et al. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996; 46: 26-9
24. Göschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies - therapeutic consequences. Exp Neurol 1997; 147: 96-102
25. Wenzel RG. Pharmacology of botulinum neurotoxin serotype A. Am J Health Syst Pharm 2004; 61 Suppl. 6: S5-10
26. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003; 60: 1186-8
27. Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005; 20: 592-7
28. Bigalke H. Properties of pharmaceutical products of botulinum neurotoxins. In: Jankovic J, Albanese A, Atassi MZ, et al., editors. Botulinum toxin: Therapeutic clinical practice and science. Philadelphia (PA): Saunders Elsevier, 2009: 389-97
29. Frevert J. Xeomin is free from complexing proteins. Toxicon 2009; 54: 697-701
30. Frevert J. Xeomin: An innovative new botulinum toxin type A. Eur J Neurol 2009; 16 Suppl. 2: 11-3
31. Eisele KH, Taylor HV, Bluemell J. Immunogenicity of NT 201 (Xeomin®) in Cynomolgus monkeys following repeated, high dose injections [poster]. 44th Annual Interagency Botulism Research Coordinating Committee (IBRCC) Meeting; 2007 Oct 14-18; Asilomar (CA)
32. Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia. Drugs 2007; 67: 669-83
33. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: A help or a hindrance? Biologics 2010; 4: 325-32
34. Electronic Medicines Compendium (eMC). XEOMIN® 50 U: Summary of product characteristics. 2011 [online]. Available from URL: Http://medicines. org.uk/EMC/medicine/24582/SPC/Xeomin+50+Units/ [Accessed 2012 Feb 13]
35. Brin MF, Comella CL, Jankovic J, et al. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 2008; 23: 1353-60
36. Minnasch P. Presence of neutralising antibodies in a patient population with cervical dystonia prior to clinical study entry [poster]. American Academy of Neurology Annual Meeting; 2010 Apr 10-17; Honolulu (HI)
37. Mohammadi B, Buhr N, Bigalke H, et al. A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 2009; 31: 463-6
38. Müller K, Mix E, Adib Saberi F, et al. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm 2009; 116: 579-85
39. Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord 2010; 25: 2211-8
40. Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinumtoxin typeA(Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010; 16: 316-23
41. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9: 213-7
42. Herrmann J, Geth K, Mall V, et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 2004; 55: 732-5
43. Koman LA, Brashear A, Rosenfeld S, et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: A multicenter, open-label clinical trial. Pediatrics 2001; 108: 1062-71
44. European Medicines Agency (EMA). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins [online]. Available from URL: www.ema.europa.eu/pdfs/human/biosimilar/1432706en.pdf [Accessed 2011 Jan 26]
45. Schulte-Baukloh H, Bigalke H, Miller K, et al. Botulinum neurotoxin type Ain urology: Antibodies as a cause of therapy failure. Int J Urol 2008; 15: 407-15
46. Kranz G, Sycha T, Voller B, et al. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology 2008; 70: 133-6
47. Lange O, Bigalke H, Dengler R, et al. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: Much ado about nothinǧ Clin Neuropharmacol 2009; 32: 213-8
48. Shone C, Wilton-Smith P, Appleton N, et al. Monoclonal antibody-based immunoassay for type A Clostridium botulinum toxin is comparable to the mouse bioassay. Appl Environ Microbiol 1985; 50: 63-7
49. Dressler D, Dirnberger G. Botulinum toxin antibody testing: Comparison between the immunoprecipitation assay and the mouse diaphragm assay. Eur Neurol 2001; 45: 257-60
50. Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry 1999; 66: 612-6
51. Palace J, Nairne A, Hyman N, et al. A radioimmuno-precipitation assay for antibodies to botulinum A. Neurology 1998; 50: 1463-6
52. Dressler D, Lange M, Bigalke H. Mouse diaphragm assay for detection of antibodies against botulinum toxin type B. Mov Disord 2005; 20: 1617-9
53. Rasetti-Escargueil C, Lui Y, Rigsby P, et al. Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies. Toxicon 2011; 57: 1008-16
54. Hatheway CH, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York (NY): Marcel Dekker, 1994: 93-107
55. Hamjian JA, Walker FO. Serial neurophysiological studies of intramuscular botulinum-A toxin in humans. Muscle Nerve 1994; 17: 1385-92
56. Dressler D, Bigalke H, Rothwell JC. The sternocleidomastoid test: An in vivo assay to investigate botulinum toxin antibody formation in humans. J Neurol 2000; 247: 630-2
57. Birklein F, Erbguth F. Sudomotor testing discriminates between subjects with and without antibodies against botulinum toxin A: A preliminary observation. Mov Disord 2000; 15: 146-9
58. Botox®: US prescribing information. Irvine (CA): Allergan, Inc., 2010
59. Dysport®: US prescribing information. Wrexham: Ipsen Biopharm, Ltd., 2010
60. BTXA®: Prescribing information. Gansu: Lanzhou Institute of Biological Products, 2011
61. Xeomin®: US prescribing information. Merz Pharmaceuticals GmbH [online]. Available from URL: Http://www.xeomin.com/Prescribing-Information- Xeomin-26-Aug-2010.pdf [Accessed 2012 Feb 7]
62. Electronic Medicines Compendium (eMC). XEOMIN® 100 U: Summary of product characteristics, 2011 [online].Available fromURL: Http://medicines.org. uk/ EMC/medicine/24582/SPC/Xeomin+100+Units/ [Accessed 2012 Feb 13]
63. Myobloc®: US prescribing information. San Francisco (CA): Solstice Neurosciences, Inc., 2009
64. Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: A double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72: 459-62
65. Chadda S, Tilden D, Jones D, et al. Cost effectiveness of Xeomin® in the management of cervical dystonia and blepharospasm. Eur J Hosp Pharm 2009; 15: 38-46
66. Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study. Mov Disord 2005; 20: 937-44
67. Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64: 1949-51
68. Roggenkämper P, Jost WH, Bihari K, et al. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006; 113: 303-12
69. Wohlfarth K,Müller C, Sassin I, et al. Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins. Clin Neuropharmacol 2007; 30: 86-94
70. Sesardic D. Is it possible to accurately determine content of botulinum neurotoxin type A in drug products? Drugs R D 2010; 10: 91-2
71. Pickett A. Consistent biochemical data are essential for comparability of botulinum toxin type A products. Drugs R D 2011; 11: 97-8
72. Sattler G, Callander MJ, Grablowitz D, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg 2010; 36 Suppl. 4: 2146-54